Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Court Orders Takeda to Pay $6B Over Actos Diabetes Drug

By Pharmaceutical Processing | September 4, 2014

TOKYO, Sept. 4 (Kyodo) — Takeda Pharmaceutical Co. said Thursday it has been ordered by a U.S. district court to pay $6 billion in punitive damages over a lawsuit filed by a man who claimed his bladder cancer was caused by Takeda’s diabetes medicine Actos.

The ruling is in line with a U.S. jury order issued in April. The district court in Louisiana also told Japan’s top-ranked drugmaker to pay $1.27 million in compensatory damages.

Takeda plans to counter the move through legal means, including the option of appealing to a higher court, company officials said. In June, the company asked the court to redo the trial, or reduce the compensation payments.

The plaintiff in the case is from New York. He said his bladder cancer was caused by the medicine and Takeda failed to provide adequate information about the risks. The ruling suggests the court supported the argument.

Kenneth Greisman, senior vice president of Takeda Pharmaceuticals U.S.A. Inc., said in a statement, “We respectfully disagree with the judgment and await a ruling on our motion for a new trial, or alternatively, a significantly reduced punitive damage award.”

The court also ordered Takeda’s sales business partner Eli Lilly and Co. in the United States to pay $3 billion.

Actos hit the market in 1999 and became Takeda’s leading product that saw sales reach over 2 trillion yen globally. The product was sold mostly in the United States.

According to Takeda, more than 6,000 Actos-related lawsuits have been filed as of mid-July in the United States.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE